TG Therapeutics (TGTX) Financials

$53.89

$-1.50 (-2.71%)

As on 11-Sep-2026 16:00EDT

Market cap

$8,250 Mln

Revenue (TTM)

$800 Mln

P/E Ratio

20.2

P/B Ratio

14

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	799.54	616.29	329.00	233.66	2.79	6.69
Cost of Revenue	141.00	100.71	38.49	14.13	0.27	0.79
Gross Profit	658.54	515.57	290.52	219.53	2.52	5.90
Operating Expenses	522.21	392.25	248.59	198.90	220.84	350.67
Operating Profit (EBIT)	136.33	123.32	41.93	20.63	-218.32	-344.77
Other Income	--	--	--	--	--	2.31
Profit before Tax	101.60	107.39	25.59	13.06	-223.81	-348.10
Provision for Tax	-339.89	-339.79	2.21	0.39	5.50	7.45
Profit after Tax (Net Income)	441.49	447.18	23.38	12.67	-223.81	-348.10
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-182.65	-348.10

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	604.08	648.02	222.36	160.50	58.59	237.15
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	767.05	261.47	264.65	115.37	81.78	77.09
Current Liabilities	268.49	153.76	90.68	53.72	53.20	65.38
Total Liabilities	1,908.12	1,063.25	577.69	329.59	193.57	379.63

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	493.94	432.49	11.33	11.64	25.30	48.66
Current Assets	1,145.69	630.76	566.36	317.94	168.27	330.97
Total Assets	1,908.12	1,063.25	577.69	329.59	193.57	379.63
Total Debt*	754.44	260.73	253.72	110.80	83.06	79.05
Net Current Assets	877.19	477.00	475.68	264.22	115.07	265.58

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-24.77	-40.52	-31.41	-176.17	-295.63
Cash Flow from Investing Activities	--	13.80	-1.04	-50.65	-20.01	-0.33
Cash from Financing Activities	--	-89.73	128.53	72.71	-0.39	41.42
Net Cash Inflow / Outflow	--	--	--	--	-196.57	-254.55

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	2.75	2.81	0.15	0.09	-1.63	-2.63
Cash EPS ($)	2.67	2.81	0.15	0.09	-1.63	-2.62
Adjusted Book Value ($)	4.11	4.07	1.39	1.12	0.43	1.79
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.16	-0.25	-0.22	-1.28	-2.23
Free Cash Flow per Share ($)	--	-0.16	-0.25	-0.22	-1.28	-2.23

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	64.58	6.26	6.14	-97.77	-79.34
ROE (%)	70.52	102.75	12.21	11.57	-151.36	-92.03
ROA (%)	31.73	54.50	5.15	4.84	-78.09	-69.26
EBIT Margin (%)	14.04	21.76	15.08	10.99	-7,670.41	-5,119.79
Net Margin (%)	55.22	72.56	7.11	5.42	-8,036.34	-3,869.51
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	76.08	0.87	0.41	82.90	-0.58	43.01
EBIT Growth (%)	15.19	170.28	93.25	112.02	37.62	-25.42
Net Profit Growth (%)	630.24	1,812.41	84.52	105.66	35.70	-24.60
EPS Growth (%)	633.67	18.23	0.65	1.05	0.38	-0.17
Book Value Growth (%)	125.86	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	20.18	10.62	206.28	192.87	-7.25	-7.24
Price / Book Value	14.03	7.33	21.69	15.23	27.69	10.62
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	62.25	36.24	95.51	89.55	-7.24	-6.68
Close Price ($)	54.94	29.81	30.10	17.08	11.83	19.00
High Price ($)	57.38	46.48	36.84	35.67	20.69	56.74
Low Price ($)	25.28	25.28	12.84	6.46	3.48	12.62
Market Cap ($ Cr)	8,249.67	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	1.23	0.40	1.14	0.69	1.42	0.33
Short term debt to equity ratio	0.00	0.00	0.01	0.01	0.03	0.01
Current Ratio	4.27	4.10	6.25	5.92	3.16	5.06
Quick Ratio	3.72	3.29	5.03	5.18	3.16	5.42
Interest Coverage	3.71	5.02	2.07	2.04	-20.96	-60.74

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	50.22	49.59	39.27	21.87	--	20.77
Asset Turnover	0.57	0.75	0.73	0.89	0.01	0.01
Receivable days	--	128.85	100.07	39.93	91.08	37.92
Inventory Days	--	428.02	713.12	514.66	-16,266.72	-10,913.12
Payable days	--	300.65	459.18	1,040.23	64,306.74	20,414.24
Cash Conversion Cycle	--	256.22	354.01	-485.64	-80,482.38	-31,289.43

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.